世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ミクロトーム市場：製品（インスツルメント、（ロータリー）、アクセサリー（ミクロトームブレード））、用途（疾病診断、医学研究）、技術（全自動、半自動、手動）、エンドユーザー（病院、臨床検査室）別 - 2027年までの世界市場予測


Microtome Market by Product (Instruments, (Rotary), Accessories (Microtome Blades), Application (Disease Diagnosis, Medical Research), Technology (Fully Automated, Semi-automated, Manual), End User (Hospital, Clinical Labs) - Global Forecast to 2027

エンドユーザー別に見ると、病院内検査室、臨床検査室、その他のエンドユーザーに分類されます。この市場の成長は、病院の検査室で行われる特殊な診断テストの数の増加、病院内での臨床診断手順の増加、世界中の... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年5月9日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		211 295 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

エンドユーザー別に見ると、病院内検査室、臨床検査室、その他のエンドユーザーに分類されます。この市場の成長は、病院の検査室で行われる特殊な診断テストの数の増加、病院内での臨床診断手順の増加、世界中の病院数の増加、病院内での臨床診断能力の確立の傾向の増加などが主な要因となっています。

"製品別ではミクロトーム装置が予測期間中に最も高いシェアを占める"
製品に基づき、ミクロトーム市場はミクロトーム器具に区分されます。製品別では、ロータリーマイクロトーム、クライオスタットマイクロトーム、振動マイクロトーム、その他のマイクロトーム、マイクロトームアクセサリーに分類されます。ミクロトーム機器部門は、ミクロトーム市場を支配すると予想されます。ミクロトーム機器への高い支出、および様々な疾患の組織学的診断に不可欠な使用は、自動ミクロトーム市場の成長を促進する主な要因となっています。

"アジア太平洋地域は、予測期間中に最も高いCAGRを記録すると推定される。"

本レポートでは、ミクロトーム市場を北米、欧州、アジア太平洋地域、その他の地域（RoW）の4つの主要地域セグメントに区分しています。アジア太平洋地域の市場は、予測期間中に最も高い成長率を記録すると予測されます。この市場の成長は、主に中流階級の可処分所得の増加、インフラ整備、インドや中国などのアジア諸国における診断技術の浸透の高まりに起因しており、加えて、がんの発生率の上昇、世界の医療機器メーカーがアジア太平洋地域の新興国でのプレゼンスの拡大に注力していることも、主要因として挙げられます。

供給側一次面接の内訳、企業タイプ別、呼称別、地域別。

- 企業タイプ別Tier1 (32%) , Tier2 (44%) , Tier3 (24%)

- 役職別Cレベル (30%)、ディレクターレベル (34%)、その他 (36%)

- 地域別北米（40％）、欧州（28％）、アジア太平洋（20％）、その他の地域（12％）。


レポート掲載企業一覧

- ダナハーコーポレーション（米国）
- Boeckeler Instruments, Inc（米国）
- SM Scientific Instruments Pvt.(インド)
- PHCホールディングス株式会社 (日本)
- カーディナル・ヘルス社（米国）
- ブライトインスツルメンツ (イギリス)
- サクラファインテックUSA, Inc（米国）
- 金華益智医療器械有限公司（中国）
- Ted Pella, Inc（米国）
- Medimeas（インド）
- SLEE medical GmbH（ドイツ）
- ヒストラインラボラトリーズ（イタリア）
- MicroTec Laborgeräte GmbH（ドイツ）
- メディテメディカルGmbH（ドイツ）
- カムデン・インスツルメンツ(イギリス)
- ルペテック社（ブラジル）
- AGD BIOMEDICALS PVT LTD（インド）
- ラファイエット・インストゥルメント・カンパニー（アメリカ）
- マイルストーン・メディカル（アメリカ）
- Diapath S.p.A.(イタリア)
- RWD Life Science Co.LTD(中国)
- LABOID INTERNATIONAL（インド）
- Shenzhen Dakewei Biotechnology Co.(中国)
- アモス・サイエンティフィック・ピーティーワイ・リミテッド（オーストラリア）
- カムデン・インスツルメンツ(イギリス)

調査対象範囲
本レポートでは、ミクロトーム市場を製品別、地域別に調査しています。また、市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）を分析しています。利害関係者向けに市場の機会や課題を評価し、市場リーダー向けに競争環境の詳細を提供しています。また、ミクロトーム市場の成長動向、展望、全体への貢献度に関してミクロ市場を調査しています。本レポートでは、5つの主要地域に関して、市場セグメントの収益を予測しています。


レポートを購入する理由
本レポートは、以下のポイントに関する洞察を提供しています。

- 市場の浸透。ミクロトーム市場の上位25社が提供するミクロトーム製品に関する包括的な情報。レポートでは、ミクロトーム市場を製品別、地域別に分析しています。

- 市場の発展。有利な新興市場に関する包括的な情報。本レポートでは、主要な地域ごとの各種固定装置の市場について分析しています。

- 市場の多様化。マイクロトーム市場における未開拓の地域、最近の開発、投資に関する徹底的な情報。

- 競合の評価。ミクロトーム市場における主要企業の市場シェアと戦略に関する詳細な評価

ページTOPに戻る


目次

1 INTRODUCTION 29
1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS & EXCLUSIONS 29
1.3 MARKET SCOPE 30
1.3.1 YEARS COVERED FOR THE STUDY 30
1.4 CURRENCY 31
1.5 LIMITATIONS 31
1.6 MARKET STAKEHOLDERS 31
1.7 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 1 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Secondary sources 35
2.1.2 PRIMARY DATA 35
FIGURE 2 PRIMARY SOURCES 35
2.1.2.1 Key data from primary sources 36
2.1.2.2 Key industry insights 37
2.1.2.3 Breakdown of primary interviews 37
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 37
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 38
2.2 MARKET SIZE ESTIMATION 38
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: DANAHER CORPORATION 39
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 39
2.2.1 GROWTH FORECAST 40
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
FIGURE 8 TOP-DOWN APPROACH 41
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 42
FIGURE 9 DATA TRIANGULATION METHODOLOGY 42
2.4 MARKET SHARE ANALYSIS 43
2.5 ASSUMPTIONS FOR THE STUDY 43
2.6 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY 44
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 45
2.7 RISK ASSESSMENT 45
TABLE 1 RISK ASSESSMENT 45
3 EXECUTIVE SUMMARY 46
FIGURE 10 MICROTOMES MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 46
FIGURE 11 MICROTOMES MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 47
FIGURE 12 MICROTOMES MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 47
FIGURE 13 MICROTOMES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 48
FIGURE 14 GLOBAL MICROTOMES MARKET: GEOGRAPHIC SNAPSHOT 49
4 PREMIUM INSIGHTS 50
4.1 MICROTOMES MARKET OVERVIEW 50
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH 50
4.2 MICROTOMES MARKET, BY PRODUCT 50
FIGURE 16 FULLY AUTOMATED MICROTOMES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 50
4.3 ASIA PACIFIC: MICROTOMES MARKET, BY PRODUCT AND COUNTRY 51
FIGURE 17 ROTARY MICROTOMES SEGMENT WILL DOMINATE APAC MARKET DURING FORECAST PERIOD 51
4.4 GEOGRAPHIC SNAPSHOT OF MICROTOMES MARKET 52
FIGURE 18 MARKET IN CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 19 MICROTOMES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 53
5.2.1.1 Rising prevalence of cancer 53
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION,
2020 VS. 2030 VS. 2040 (MILLION) 54
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS,
2015 VS. 2018 VS. 2035 54
5.2.1.2 Growing demand for digital pathology 55
5.2.1.3 Recommendations for cancer screening 55
5.2.1.4 Availability of reimbursement 56
5.2.2 CHALLENGES 56
5.2.2.1 Lack of skilled professionals 56
TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018 57
5.2.2.2 Availability of refurbished products 57
5.2.3 OPPORTUNITIES 57
5.2.3.1 Growing focus on personalized medicine 57
5.2.3.2 Emerging economies 58
5.3 IMPACT OF COVID-19 ON MICROTOMES MARKET 58
5.4 RANGES/SCENARIOS 60
5.4.1 MICROTOMES MARKET 60
FIGURE 20 PESSIMISTIC SCENARIO 60
FIGURE 21 OPTIMISTIC SCENARIO 60
FIGURE 22 REALISTIC SCENARIO 61
5.5 VALUE CHAIN ANALYSIS 61
FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING MANUFACTURING AND ASSEMBLY PHASE 62
5.6 SUPPLY CHAIN ANALYSIS 62
FIGURE 24 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 63
5.7 TECHNOLOGY ANALYSIS 63
5.8 PORTER’S FIVE FORCES ANALYSIS 64
5.8.1 THREAT OF NEW ENTRANTS 64
5.8.2 INTENSITY OF COMPETITIVE RIVALRY 64
5.8.3 BARGAINING POWER OF BUYERS 64
5.8.4 BARGAINING POWER OF SUPPLIERS 65
5.8.5 THREAT OF SUBSTITUTES 65
5.9 KEY STAKEHOLDERS & BUYING CRITERIA 65
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 65
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 2 END USERS 65
TABLE 5 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 2 END USERS 65
5.9.2 BUYING CRITERIA 66
FIGURE 26 KEY BUYING CRITERIA FOR TOP 2 END USERS 66
TABLE 6 KEY BUYING CRITERIA FOR TOP 2 END USERS 66
5.10 REGULATORY LANDSCAPE 67
TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES
GOVERNING MICROTOMES MARKET 67
5.11 PATENT ANALYSIS 68
5.12 KEY CONFERENCES & EVENTS IN 2022 69
TABLE 8 LIST OF CONFERENCES & EVENTS 69
5.13 PRICING ANALYSIS 69
TABLE 9 PRICE RANGE FOR MICROTOMES 69
5.14 TRADE ANALYSIS 70
TABLE 10 IMPORT DATA FOR MICROTOMES AND PARTS AND ACCESSORIES OF INSTRUMENTS & APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS,
BY COUNTRY, 2016–2020 (USD MILLION) 70
TABLE 11 EXPORT DATA FOR MICROTOMES AND PARTS AND ACCESSORIES OF INSTRUMENTS & APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS,
BY COUNTRY, 2016–2020 (USD MILLION) 71
5.15 ECOSYSTEM ANALYSIS 71
5.15.1 ROLE IN ECOSYSTEM 72
5.15.2 KEY PLAYERS OPERATING IN MICROTOMES MARKET 72
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 73
 
6 MICROTOMES MARKET, BY PRODUCT 74
6.1 INTRODUCTION 75
TABLE 12 MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 75
TABLE 13 MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 75
6.2 MICROTOME INSTRUMENTS 76
TABLE 14 MICROTOME INSTRUMENTS MARKET, BY TYPE, 2017–2020 (USD MILLION) 76
TABLE 15 MICROTOME INSTRUMENTS MARKET, BY TYPE, 2021–2027 (USD MILLION) 76
TABLE 16 MICROTOME INSTRUMENTS MARKET, BY REGION,
2017–2020 (USD MILLION) 76
TABLE 17 MICROTOME INSTRUMENTS MARKET, BY REGION,
2021–2027 (USD MILLION) 77
6.2.1 ROTARY MICROTOMES 77
6.2.1.1 Rotary microtomes are widely used in histology laboratories 77
TABLE 18 ROTARY MICROTOMES OFFERED BY MARKET PLAYERS 77
TABLE 19 ROTARY MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION) 78
TABLE 20 ROTARY MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION) 78
6.2.2 CRYOSTAT MICROTOMES 79
6.2.2.1 Cryostat microtomes provide immediate results by quickly, reliably, and safely cutting accurate frozen sections 79
TABLE 21 CRYOSTAT MICROTOMES OFFERED BY MARKET PLAYERS 79
TABLE 22 CRYOSTAT MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION) 80
TABLE 23 CRYOSTAT MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION) 80
6.2.3 VIBRATING MICROTOMES 80
6.2.3.1 Vibrating microtomes are designed to cut fresh tissue specimens 80
TABLE 24 VIBRATING MICROTOMES OFFERED BY MARKET PLAYERS 81
TABLE 25 VIBRATING MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION) 81
TABLE 26 VIBRATING MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION) 81
6.2.4 OTHER MICROTOMES 82
TABLE 27 OTHER MICROTOMES OFFERED BY MARKET PLAYERS 83
TABLE 28 OTHER MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION) 83
TABLE 29 OTHER MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION) 84
6.3 MICROTOME ACCESSORIES 84
TABLE 30 MICROTOME ACCESSORIES MARKET, BY TYPE, 2017–2020 (USD MILLION) 84
TABLE 31 MICROTOME ACCESSORIES MARKET, BY TYPE, 2021–2027 (USD MILLION) 84
6.3.1 MICROTOME BLADES 85
6.3.1.1 Adoption of disposable blades has increased among end users 85
TABLE 32 MICROTOME BLADES OFFERED BY MARKET PLAYERS 85
TABLE 33 MICROTOME BLADES MARKET, BY REGION, 2017–2020 (USD MILLION) 86
TABLE 34 MICROTOME BLADES MARKET, BY REGION, 2021–2027 (USD MILLION) 86
6.3.2 OTHER MICROTOME ACCESSORIES 86
TABLE 35 OTHER MICROTOME ACCESSORIES OFFERED BY MARKET PLAYERS 87
TABLE 36 OTHER MICROTOME ACCESSORIES MARKET, BY REGION,
2017–2020 (USD MILLION) 88
TABLE 37 OTHER MICROTOME ACCESSORIES MARKET, BY REGION,
2021–2027 (USD MILLION) 88
7 MICROTOMES MARKET, BY TECHNOLOGY 89
7.1 INTRODUCTION 90
TABLE 38 MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 90
TABLE 39 MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 90
7.2 MANUAL MICROTOMES 90
7.2.1 LOWER COST AND USER COMFORT ASSOCIATED WITH THESE MICROTOMES ARE DRIVING THEIR ADOPTION 90
TABLE 40 MANUAL MICROTOMES OFFERED BY MARKET PLAYERS 91
TABLE 41 MANUAL MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION) 91
TABLE 42 MANUAL MICROTOMES MARKET, BY REGION, 2021–2027 USD MILLION) 91
7.3 SEMI-AUTOMATED MICROTOMES 92
7.3.1 SEMI-AUTOMATED MICROTOMES SEGMENT TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 92
TABLE 43 SEMI-AUTOMATED MICROTOMES OFFERED BY MARKET PLAYERS 92
TABLE 44 SEMI-AUTOMATED MICROTOMES MARKET, BY REGION,
2017–2020 (USD MILLION) 92
TABLE 45 SEMI-AUTOMATED MICROTOMES MARKET, BY REGION,
2021–2027 (USD MILLION) 93
7.4 FULLY AUTOMATED MICROTOMES 93
7.4.1 LACK OF CLINICAL LABORATORY TECHNICIANS AND HIGH PREVALENCE OF CANCER HAVE DRIVEN SEGMENT GROWTH 93
TABLE 46 FULLY AUTOMATED MICROTOMES OFFERED BY MARKET PLAYERS 93
TABLE 47 FULLY AUTOMATED MICROTOMES MARKET, BY REGION,
2017–2020 (USD MILLION) 94
TABLE 48 FULLY AUTOMATED MICROTOMES MARKET, BY REGION,
2021–2027 (USD MILLION) 94
8 MICROTOMES MARKET, BY APPLICATION 95
8.1 INTRODUCTION 96
TABLE 49 MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 96
TABLE 50 MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 96
8.2 DISEASE DIAGNOSIS 96
8.2.1 EXPANDING POOL OF GERIATRIC PATIENTS AND INCREASING DIAGNOSIS OF CHRONIC DISEASES DRIVING SEGMENT GROWTH 96
TABLE 51 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS.
2030 VS. 2040 (MILLION) 97
TABLE 52 MICROTOMES MARKET FOR DISEASE DIAGNOSIS, BY REGION,
2017–2020 (USD MILLION) 97
TABLE 53 MICROTOMES MARKET FOR DISEASE DIAGNOSIS, BY REGION,
2021–2027 (USD MILLION) 97
8.3 MEDICAL RESEARCH 98
8.3.1 INCREASING RESEARCH ACTIVITIES TO DRIVE ADOPTION OF MICROTOMES 98
TABLE 54 MICROTOMES MARKET FOR MEDICAL RESEARCH, BY REGION,
2017–2020 (USD MILLION) 98
TABLE 55 MICROTOMES MARKET FOR MEDICAL RESEARCH, BY REGION,
2021–2027 (USD MILLION) 98
9 MICROTOMES MARKET, BY END USER 99
9.1 INTRODUCTION 100
TABLE 56 MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 100
TABLE 57 MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 100
9.2 HOSPITAL LABORATORIES 100
9.2.1 HOSPITAL LABORATORIES ACCOUNTED FOR LARGEST
MARKET SHARE IN 2021 100
TABLE 58 MICROTOMES MARKET FOR HOSPITAL LABORATORIES, BY REGION,
2017–2020 (USD MILLION) 101
TABLE 59 MICROTOMES MARKET FOR HOSPITAL LABORATORIES, BY REGION,
2021–2027 (USD MILLION) 101
9.3 CLINICAL LABORATORIES 102
9.3.1 PRESENCE OF ROBUST INFRASTRUCTURE TO PERFORM TESTS IN HIGH VOLUMES IS ESTIMATED TO DRIVE MARKET GROWTH 102
TABLE 60 MICROTOMES MARKET FOR CLINICAL LABORATORIES, BY REGION,
2017–2020 (USD MILLION) 102
TABLE 61 MICROTOMES MARKET FOR CLINICAL LABORATORIES, BY REGION,
2021–2027 (USD MILLION) 102
9.4 OTHER END USERS 103
TABLE 62 MICROTOMES MARKET FOR OTHER END USERS, BY REGION,
2017–2020 (USD MILLION) 103
TABLE 63 MICROTOMES MARKET FOR OTHER END USERS, BY REGION,
2021–2027 (USD MILLION) 103
10 MICROTOMES MARKET, BY REGION 104
10.1 INTRODUCTION 105
TABLE 64 MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION) 105
TABLE 65 MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION) 105
10.2 NORTH AMERICA 106
FIGURE 27 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035 106
FIGURE 28 NORTH AMERICA: MICROTOMES MARKET SNAPSHOT 107
TABLE 66 NORTH AMERICA: MICROTOMES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 108
TABLE 67 NORTH AMERICA: MICROTOMES MARKET, BY COUNTRY,
2021–2027 (USD MILLION) 108
TABLE 68 NORTH AMERICA: MICROTOMES MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 108
TABLE 69 NORTH AMERICA: MICROTOMES MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 108
TABLE 70 NORTH AMERICA: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2017–2020 (USD MILLION) 109
TABLE 71 NORTH AMERICA: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2021–2027 (USD MILLION) 109
TABLE 72 NORTH AMERICA: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 109
TABLE 73 NORTH AMERICA: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 110
TABLE 74 NORTH AMERICA: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 110
TABLE 75 NORTH AMERICA: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 110
TABLE 76 NORTH AMERICA: MICROTOMES MARKET, BY END USER,
2017–2020 (USD MILLION) 110
TABLE 77 NORTH AMERICA: MICROTOMES MARKET, BY END USER,
2021–2027 (USD MILLION) 111
10.2.1 US 111
10.2.1.1 High burden of cancer and numerous conferences on anatomic pathology to drive market growth 111
TABLE 78 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 111
TABLE 79 US: KEY MACROINDICATORS 112
TABLE 80 US: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 112
TABLE 81 US: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 112
TABLE 82 US: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 113
TABLE 83 US: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 113
TABLE 84 US: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 113
TABLE 85 US: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 113
TABLE 86 US: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 114
TABLE 87 US: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 114
10.2.2 CANADA 114
10.2.2.1 Availability of research funding and rising incidence of cancer to drive market growth 114
TABLE 88 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 115
TABLE 89 CANADA: KEY MACROINDICATORS 115
TABLE 90 CANADA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 115
TABLE 91 CANADA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 116
TABLE 92 CANADA: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 116
TABLE 93 CANADA: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 116
TABLE 94 CANADA: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 116
TABLE 95 CANADA: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 117
TABLE 96 CANADA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 117
TABLE 97 CANADA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 117
10.3 EUROPE 117
FIGURE 29 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 118
TABLE 98 EUROPE: MICROTOMES MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 118
TABLE 99 EUROPE: MICROTOMES MARKET, BY COUNTRY, 2021–2027 (USD MILLION) 118
TABLE 100 EUROPE: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 119
TABLE 101 EUROPE: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 119
TABLE 102 EUROPE: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2017–2020 (USD MILLION) 119
TABLE 103 EUROPE: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2021–2027 (USD MILLION) 119
TABLE 104 EUROPE: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 120
TABLE 105 EUROPE: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 120
TABLE 106 EUROPE: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 120
TABLE 107 EUROPE: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 120
TABLE 108 EUROPE: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 121
TABLE 109 EUROPE: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 121
10.3.1 GERMANY 121
10.3.1.1 Increasing prevalence of chronic diseases to drive market growth 121
TABLE 110 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 122
TABLE 111 GERMANY: MICROTOMES MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 122
TABLE 112 GERMANY: MICROTOMES MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 122
TABLE 113 GERMANY: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 123
TABLE 114 GERMANY: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 123
TABLE 115 GERMANY: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 123
TABLE 116 GERMANY: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 123
TABLE 117 GERMANY: MICROTOMES MARKET, BY END USER,
2017–2020 (USD MILLION) 124
TABLE 118 GERMANY: MICROTOMES MARKET, BY END USER,
2021–2027 (USD MILLION) 124
10.3.2 FRANCE 124
10.3.2.1 High prevalence of cancer to support market growth in France 124
TABLE 119 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 125
TABLE 120 FRANCE: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 125
TABLE 121 FRANCE: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 125
TABLE 122 FRANCE: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 125
TABLE 123 FRANCE: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 126
TABLE 124 FRANCE: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 126
TABLE 125 FRANCE: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 126
TABLE 126 FRANCE: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 126
TABLE 127 FRANCE: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 127
10.3.3 UK 127
10.3.3.1 Favorable government initiatives to drive market growth 127
TABLE 128 UK: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 127
TABLE 129 UK: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 128
TABLE 130 UK: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 128
TABLE 131 UK: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 128
TABLE 132 UK: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 128
TABLE 133 UK: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 129
TABLE 134 UK: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 129
TABLE 135 UK: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 129
10.3.4 ITALY 129
10.3.4.1 High prevalence of cancer and increasing per capita healthcare spending to support market growth in Italy 129
TABLE 136 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 130
TABLE 137 ITALY: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 130
TABLE 138 ITALY: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 131
TABLE 139 ITALY: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 131
TABLE 140 ITALY: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 131
TABLE 141 ITALY: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 131
TABLE 142 ITALY: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 132
TABLE 143 ITALY: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 132
TABLE 144 ITALY: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 132
10.3.5 SPAIN 132
10.3.5.1 High incidence of chronic diseases to drive market growth in Spain 132
TABLE 145 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 133
TABLE 146 SPAIN: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 133
TABLE 147 SPAIN: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 133
TABLE 148 SPAIN: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 134
TABLE 149 SPAIN: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 134
TABLE 150 SPAIN: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 134
TABLE 151 SPAIN: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 134
TABLE 152 SPAIN: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 135
TABLE 153 SPAIN: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 135
10.3.6 REST OF EUROPE 135
TABLE 154 LUNG CANCER INCIDENCE IN KEY ROE COUNTRIES, 2020 VS. 2040 136
TABLE 155 LIVER CANCER INCIDENCE IN KEY ROE COUNTRIES, 2020 VS. 2040 136
TABLE 156 ROE: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 137
TABLE 157 ROE: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 137
TABLE 158 ROE: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 137
TABLE 159 ROE: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 137
TABLE 160 ROE: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 138
TABLE 161 ROE: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 138
TABLE 162 ROE: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 138
TABLE 163 ROE: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 138
10.4 ASIA PACIFIC 139
FIGURE 30 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035 139
FIGURE 31 ASIA PACIFIC: MICROTOMES MARKET SNAPSHOT 140
TABLE 164 ASIA PACIFIC: MICROTOMES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 140
TABLE 165 ASIA PACIFIC: MICROTOMES MARKET, BY COUNTRY,
2021–2027 (USD MILLION) 141
TABLE 166 ASIA PACIFIC: MICROTOMES MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 141
TABLE 167 ASIA PACIFIC: MICROTOMES MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 141
TABLE 168 ASIA PACIFIC: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2017–2020 (USD MILLION) 141
TABLE 169 ASIA PACIFIC: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2021–2027 (USD MILLION) 142
TABLE 170 ASIA PACIFIC: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 142
TABLE 171 ASIA PACIFIC: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 142
TABLE 172 ASIA PACIFIC: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 142
TABLE 173 ASIA PACIFIC: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 143
TABLE 174 ASIA PACIFIC: MICROTOMES MARKET, BY END USER,
2017–2020 (USD MILLION) 143
TABLE 175 ASIA PACIFIC: MICROTOMES MARKET, BY END USER,
2021–2027 (USD MILLION) 143
10.4.1 JAPAN 143
10.4.1.1 Presence of well-developed healthcare system to support market growth in Japan 143
TABLE 176 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 144
TABLE 177 JAPAN: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 144
TABLE 178 JAPAN: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 145
TABLE 179 JAPAN: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 145
TABLE 180 JAPAN: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 145
TABLE 181 JAPAN: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 145
TABLE 182 JAPAN: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 146
TABLE 183 JAPAN: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 146
TABLE 184 JAPAN: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 146
10.4.2 CHINA 146
10.4.2.1 Rising healthcare expenditure to drive market growth in China 146
TABLE 185 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 147
TABLE 186 CHINA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 147
TABLE 187 CHINA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 147
TABLE 188 CHINA: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 148
TABLE 189 CHINA: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 148
TABLE 190 CHINA: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 148
TABLE 191 CHINA: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 148
TABLE 192 CHINA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 149
TABLE 193 CHINA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 149
10.4.3 INDIA 149
10.4.3.1 Growing healthcare sector to drive market growth in India 149
TABLE 194 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 149
TABLE 195 INDIA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 150
TABLE 196 INDIA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 150
TABLE 197 INDIA: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 150
TABLE 198 INDIA: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 151
TABLE 199 INDIA: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 151
TABLE 200 INDIA: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 151
TABLE 201 INDIA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 151
TABLE 202 INDIA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 152
10.4.4 REST OF ASIA PACIFIC 152
TABLE 203 ROAPAC: INCIDENCE OF CANCER, BY COUNTRY, 2020 VS. 2040 153
TABLE 204 ROAPAC: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 153
TABLE 205 ROAPAC: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 153
TABLE 206 ROAPAC: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 153
TABLE 207 ROAPAC: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 154
TABLE 208 ROAPAC: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 154
TABLE 209 ROAPAC: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 154
TABLE 210 ROAPAC: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 154
TABLE 211 ROAPAC: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 155
10.5 REST OF THE WORLD 155
TABLE 212 LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025 155
TABLE 213 LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025 155
TABLE 214 BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025 156
TABLE 215 AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 156
TABLE 216 ROW: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 156
TABLE 217 ROW: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 157
TABLE 218 ROW: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2017–2020 (USD MILLION) 157
TABLE 219 ROW: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2021–2027 (USD MILLION) 157
TABLE 220 ROW: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 157
TABLE 221 ROW: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 158
TABLE 222 ROW: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 158
TABLE 223 ROW: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 158
TABLE 224 ROW: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 158
TABLE 225 ROW: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 159
11 COMPETITIVE LANDSCAPE 160
11.1 OVERVIEW 160
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 160
TABLE 226 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 160
11.3 MARKET SHARE ANALYSIS 161
TABLE 227 MICROTOMES MARKET: DEGREE OF COMPETITION 161
11.4 COMPANY EVALUATION MATRIX 162
11.4.1 STARS 162
11.4.2 EMERGING LEADERS 163
11.4.3 PERVASIVE PLAYERS 163
11.4.4 PARTICIPANTS 163
FIGURE 32 COMPANY EVALUATION MATRIX: MICROTOMES MARKET 163
11.5 COMPANY EVALUATION MATRIX FOR SMES/START-UPS 164
11.5.1 PROGRESSIVE COMPANIES 164
11.5.2 STARTING BLOCKS 164
11.5.3 RESPONSIVE COMPANIES 164
11.5.4 DYNAMIC COMPANIES 164
FIGURE 33 COMPANY EVALUATION MATRIX FOR SMES/START-UPS:
MICROTOMES MARKET 165
11.6 COMPANY FOOTPRINT ANALYSIS 166
TABLE 228 OVERALL FOOTPRINT OF COMPANIES 166
TABLE 229 REGIONAL FOOTPRINT OF COMPANIES 167
TABLE 230 PRODUCT FOOTPRINT OF COMPANIES 168
11.7 COMPETITIVE BENCHMARKING 169
TABLE 231 MICROTOMES MARKET: DETAILED LIST OF KEY START-UPS/SMES 169
11.8 COMPETITIVE SCENARIO 170
11.8.1 PRODUCT LAUNCHES 170
TABLE 232 KEY PRODUCT LAUNCHES 170
11.8.2 DEALS 170
TABLE 233 KEY DEALS 170
11.8.3 OTHER DEVELOPMENTS 170
TABLE 234 OTHER KEY DEVELOPMENTS 170
12 COMPANY PROFILES 171
12.1 KEY PLAYERS 171
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION 171
TABLE 235 DANAHER CORPORATION: BUSINESS OVERVIEW 171
FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 172
12.1.2 PHC HOLDINGS CORPORATION 175
TABLE 236 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW 175
FIGURE 35 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021) 176
12.1.3 CARDINAL HEALTH 178
TABLE 237 CARDINAL HEALTH: BUSINESS OVERVIEW 178
FIGURE 36 CARDINAL HEALTH: COMPANY SNAPSHOT (2021) 179
12.1.4 BOECKELER INSTRUMENTS, INC. 181
TABLE 238 BOECKELER INSTRUMENTS, INC.: BUSINESS OVERVIEW 181
12.1.5 BRIGHT INSTRUMENTS LTD. 183
TABLE 239 BRIGHT INSTRUMENTS LTD.: BUSINESS OVERVIEW 183
12.1.6 ERMA INC. 184
TABLE 240 ERMA INC.: BUSINESS OVERVIEW 184
12.1.7 HISTO-LINE LABORATORIES 185
TABLE 241 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW 185
12.1.8 JINHUA YIDI MEDICAL APPLIANCE CO., LTD. 187
TABLE 242 JINHUA YIDI MEDICAL APPLIANCE CO., LTD.: BUSINESS OVERVIEW 187
12.1.9 MEDIMEAS 189
TABLE 243 MEDIMEAS: BUSINESS OVERVIEW 189
12.1.10 MEDITE MEDICAL GMBH 191
TABLE 244 MEDITE MEDICAL GMBH: BUSINESS OVERVIEW 191
12.1.11 MICROTEC LABORGERÄTE GMBH 192
TABLE 245 MICROTEC LABORGERÄTE GMBH: BUSINESS OVERVIEW 192
12.1.12 SAKURA FINETEK USA, INC. 194
TABLE 246 SAKURA FINETEK USA, INC.: BUSINESS OVERVIEW 194
12.1.13 SLEE MEDICAL GMBH 196
TABLE 247 SLEE MEDICAL GMBH: BUSINESS OVERVIEW 196
12.1.14 SM SCIENTIFIC INSTRUMENTS PVT. LTD. 198
TABLE 248 SM SCIENTIFIC INSTRUMENTS PVT. LTD.: BUSINESS OVERVIEW 198
12.1.15 TED PELLA, INC. 200
TABLE 249 TED PELLA, INC.: BUSINESS OVERVIEW 200
12.2 OTHER PLAYERS 202
12.2.1 AGD BIOMEDICALS PVT. LTD. 202
TABLE 250 AGD BIOMEDICALS PVT. LTD.: BUSINESS OVERVIEW 202
12.2.2 AMOS SCIENTIFIC PTY LTD. 203
TABLE 251 AMOS SCIENTIFIC PTY LTD.: BUSINESS OVERVIEW 203
12.2.3 CAMPDEN INSTRUMENTS LTD. 204
TABLE 252 CAMPDEN INSTRUMENTS LTD.: BUSINESS OVERVIEW 204
12.2.4 DIAPATH S.P.A. 205
TABLE 253 DIAPATH S.P.A.: BUSINESS OVERVIEW 205
12.2.5 LABOID INTERNATIONAL 207
TABLE 254 LABOID INTERNATIONAL: BUSINESS OVERVIEW 207
12.2.6 LAFAYETTE INSTRUMENT COMPANY 208
TABLE 255 LAFAYETTE INSTRUMENT COMPANY: BUSINESS OVERVIEW 208
12.2.7 LUPETEC 209
TABLE 256 LUPETEC: BUSINESS OVERVIEW 209
12.2.8 MILESTONE MEDICAL 210
TABLE 257 MILESTONE MEDICAL: BUSINESS OVERVIEW 210
12.2.9 RWD LIFE SCIENCE CO., LTD. 211
TABLE 258 RWD LIFE SCIENCE CO., LTD.: BUSINESS OVERVIEW 211
12.2.10 SHENZHEN DAKEWEI BIOTECHNOLOGY CO., LTD. 212
TABLE 259 SHENZHEN DAKEWEI BIOTECHNOLOGY CO., LTD.: BUSINESS OVERVIEW 212
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 213
13.1 DISCUSSION GUIDE 213
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 216
13.3 AVAILABLE CUSTOMIZATIONS 218
13.4 RELATED REPORTS 218
13.5 AUTHOR DETAILS 219

　

ページTOPに戻る


　

Summary

Based on End user the market is classified into, The hospital laboratories, clinical laboratories, and other end users . The growth of this market is majorly driven by the increasing number of specialty diagnostic tests performed in hospital laboratories, rising number of in-house clinical diagnostic procedures in hospitals, rising number of hospitals across the globe, and the growing trend of establishing in-house clinical diagnostic capabilities in hospitals.

“Microtome instruments in the product segment to witness the highest shares during the forecast period.”
Based on the product, the microtome market is segmented into Microtome Instruments: Rotary Microtomes, Cryostat Microtomes, Vibrating Microtomes, Other Microtomes, and Microtome Accessories. The microtome instruments segment is expected to dominate the microtome market. High expenditure on microtome instruments and their essential use in the histological diagnosis of various diseases are the key factors driving the growth of the automated microtome market.

“Asia Pacific is estimated to register the highest CAGR during the forecast period.”

In this report, the microtome market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by the rising disposable income of the middle-class population, infrastructural developments, and the rising penetration of diagnostic technologies in Asian countries such as India and China in addition, the rising incidence of cancer and the growing focus of global medical device companies on expanding their presence in emerging Asia Pacific countries are some of the key factors.

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (32%) , Tier 2 (44%), and Tier 3 (24%)

• By Designation: C-level (30%), Director-level (34%), and Others (36%)

• By Region: North America (40%), Europe (28%), AsiaPacific (20%), and Rest of the World(12%)


List of Companies Profiled in the Report

• Danaher Corporation (US)
• Boeckeler Instruments, Inc (US)
• SM Scientific Instruments Pvt. Ltd. (India)
• PHC holdings corporation (Japan)
• Cardinal Health (US)
• Bright Instruments (UK)
• Sakura Finetek USA, Inc (US)
• Jinhua Yidi Medical Equipment Co., Ltd (China)
• Ted Pella, Inc (US)
• Medimeas (India)
• SLEE medical GmbH (Germany)
• Histo-Line Laboratories (Italy)
• microTec Laborgeräte GmbH (Germany)
• MEDITE Medical GmbH (Germany)
• Campden Instruments. (UK)
• Lupetec (Brazil)
• AGD BIOMEDICALS PVT LTD (India)
• Lafayette Instrument Company (US)
• MILESTONE MEDICAL (US)
• Diapath S.p.A. (Italy)
• RWD Life Science Co., LTD (China)
• LABOID INTERNATIONAL (India)
• Shenzhen Dakewei Biotechnology Co., Ltd. (China)
• Amos scientific Pty Ltd (Australia)
• Campden Instruments. (UK)

Research Coverage:
This report studies the microtome market based on product, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total microtome market. The report forecasts the revenue of the market segments with respect to five major regions.


Reasons to Buy the Report:
The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on microtome products offered by the top 25 players in the microtome market. The report analyzes the microtome market by product, and region.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.

• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the microtme market

• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the microtome market



ページTOPに戻る


Table of Contents

1 INTRODUCTION 29
1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS & EXCLUSIONS 29
1.3 MARKET SCOPE 30
1.3.1 YEARS COVERED FOR THE STUDY 30
1.4 CURRENCY 31
1.5 LIMITATIONS 31
1.6 MARKET STAKEHOLDERS 31
1.7 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 1 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Secondary sources 35
2.1.2 PRIMARY DATA 35
FIGURE 2 PRIMARY SOURCES 35
2.1.2.1 Key data from primary sources 36
2.1.2.2 Key industry insights 37
2.1.2.3 Breakdown of primary interviews 37
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 37
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 38
2.2 MARKET SIZE ESTIMATION 38
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: DANAHER CORPORATION 39
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 39
2.2.1 GROWTH FORECAST 40
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
FIGURE 8 TOP-DOWN APPROACH 41
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 42
FIGURE 9 DATA TRIANGULATION METHODOLOGY 42
2.4 MARKET SHARE ANALYSIS 43
2.5 ASSUMPTIONS FOR THE STUDY 43
2.6 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY 44
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 45
2.7 RISK ASSESSMENT 45
TABLE 1 RISK ASSESSMENT 45
3 EXECUTIVE SUMMARY 46
FIGURE 10 MICROTOMES MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 46
FIGURE 11 MICROTOMES MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 47
FIGURE 12 MICROTOMES MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 47
FIGURE 13 MICROTOMES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 48
FIGURE 14 GLOBAL MICROTOMES MARKET: GEOGRAPHIC SNAPSHOT 49
4 PREMIUM INSIGHTS 50
4.1 MICROTOMES MARKET OVERVIEW 50
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH 50
4.2 MICROTOMES MARKET, BY PRODUCT 50
FIGURE 16 FULLY AUTOMATED MICROTOMES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 50
4.3 ASIA PACIFIC: MICROTOMES MARKET, BY PRODUCT AND COUNTRY 51
FIGURE 17 ROTARY MICROTOMES SEGMENT WILL DOMINATE APAC MARKET DURING FORECAST PERIOD 51
4.4 GEOGRAPHIC SNAPSHOT OF MICROTOMES MARKET 52
FIGURE 18 MARKET IN CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 19 MICROTOMES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 53
5.2.1.1 Rising prevalence of cancer 53
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION,
2020 VS. 2030 VS. 2040 (MILLION) 54
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS,
2015 VS. 2018 VS. 2035 54
5.2.1.2 Growing demand for digital pathology 55
5.2.1.3 Recommendations for cancer screening 55
5.2.1.4 Availability of reimbursement 56
5.2.2 CHALLENGES 56
5.2.2.1 Lack of skilled professionals 56
TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018 57
5.2.2.2 Availability of refurbished products 57
5.2.3 OPPORTUNITIES 57
5.2.3.1 Growing focus on personalized medicine 57
5.2.3.2 Emerging economies 58
5.3 IMPACT OF COVID-19 ON MICROTOMES MARKET 58
5.4 RANGES/SCENARIOS 60
5.4.1 MICROTOMES MARKET 60
FIGURE 20 PESSIMISTIC SCENARIO 60
FIGURE 21 OPTIMISTIC SCENARIO 60
FIGURE 22 REALISTIC SCENARIO 61
5.5 VALUE CHAIN ANALYSIS 61
FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING MANUFACTURING AND ASSEMBLY PHASE 62
5.6 SUPPLY CHAIN ANALYSIS 62
FIGURE 24 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 63
5.7 TECHNOLOGY ANALYSIS 63
5.8 PORTER’S FIVE FORCES ANALYSIS 64
5.8.1 THREAT OF NEW ENTRANTS 64
5.8.2 INTENSITY OF COMPETITIVE RIVALRY 64
5.8.3 BARGAINING POWER OF BUYERS 64
5.8.4 BARGAINING POWER OF SUPPLIERS 65
5.8.5 THREAT OF SUBSTITUTES 65
5.9 KEY STAKEHOLDERS & BUYING CRITERIA 65
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 65
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 2 END USERS 65
TABLE 5 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 2 END USERS 65
5.9.2 BUYING CRITERIA 66
FIGURE 26 KEY BUYING CRITERIA FOR TOP 2 END USERS 66
TABLE 6 KEY BUYING CRITERIA FOR TOP 2 END USERS 66
5.10 REGULATORY LANDSCAPE 67
TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES
GOVERNING MICROTOMES MARKET 67
5.11 PATENT ANALYSIS 68
5.12 KEY CONFERENCES & EVENTS IN 2022 69
TABLE 8 LIST OF CONFERENCES & EVENTS 69
5.13 PRICING ANALYSIS 69
TABLE 9 PRICE RANGE FOR MICROTOMES 69
5.14 TRADE ANALYSIS 70
TABLE 10 IMPORT DATA FOR MICROTOMES AND PARTS AND ACCESSORIES OF INSTRUMENTS & APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS,
BY COUNTRY, 2016–2020 (USD MILLION) 70
TABLE 11 EXPORT DATA FOR MICROTOMES AND PARTS AND ACCESSORIES OF INSTRUMENTS & APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS,
BY COUNTRY, 2016–2020 (USD MILLION) 71
5.15 ECOSYSTEM ANALYSIS 71
5.15.1 ROLE IN ECOSYSTEM 72
5.15.2 KEY PLAYERS OPERATING IN MICROTOMES MARKET 72
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 73
 
6 MICROTOMES MARKET, BY PRODUCT 74
6.1 INTRODUCTION 75
TABLE 12 MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 75
TABLE 13 MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 75
6.2 MICROTOME INSTRUMENTS 76
TABLE 14 MICROTOME INSTRUMENTS MARKET, BY TYPE, 2017–2020 (USD MILLION) 76
TABLE 15 MICROTOME INSTRUMENTS MARKET, BY TYPE, 2021–2027 (USD MILLION) 76
TABLE 16 MICROTOME INSTRUMENTS MARKET, BY REGION,
2017–2020 (USD MILLION) 76
TABLE 17 MICROTOME INSTRUMENTS MARKET, BY REGION,
2021–2027 (USD MILLION) 77
6.2.1 ROTARY MICROTOMES 77
6.2.1.1 Rotary microtomes are widely used in histology laboratories 77
TABLE 18 ROTARY MICROTOMES OFFERED BY MARKET PLAYERS 77
TABLE 19 ROTARY MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION) 78
TABLE 20 ROTARY MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION) 78
6.2.2 CRYOSTAT MICROTOMES 79
6.2.2.1 Cryostat microtomes provide immediate results by quickly, reliably, and safely cutting accurate frozen sections 79
TABLE 21 CRYOSTAT MICROTOMES OFFERED BY MARKET PLAYERS 79
TABLE 22 CRYOSTAT MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION) 80
TABLE 23 CRYOSTAT MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION) 80
6.2.3 VIBRATING MICROTOMES 80
6.2.3.1 Vibrating microtomes are designed to cut fresh tissue specimens 80
TABLE 24 VIBRATING MICROTOMES OFFERED BY MARKET PLAYERS 81
TABLE 25 VIBRATING MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION) 81
TABLE 26 VIBRATING MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION) 81
6.2.4 OTHER MICROTOMES 82
TABLE 27 OTHER MICROTOMES OFFERED BY MARKET PLAYERS 83
TABLE 28 OTHER MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION) 83
TABLE 29 OTHER MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION) 84
6.3 MICROTOME ACCESSORIES 84
TABLE 30 MICROTOME ACCESSORIES MARKET, BY TYPE, 2017–2020 (USD MILLION) 84
TABLE 31 MICROTOME ACCESSORIES MARKET, BY TYPE, 2021–2027 (USD MILLION) 84
6.3.1 MICROTOME BLADES 85
6.3.1.1 Adoption of disposable blades has increased among end users 85
TABLE 32 MICROTOME BLADES OFFERED BY MARKET PLAYERS 85
TABLE 33 MICROTOME BLADES MARKET, BY REGION, 2017–2020 (USD MILLION) 86
TABLE 34 MICROTOME BLADES MARKET, BY REGION, 2021–2027 (USD MILLION) 86
6.3.2 OTHER MICROTOME ACCESSORIES 86
TABLE 35 OTHER MICROTOME ACCESSORIES OFFERED BY MARKET PLAYERS 87
TABLE 36 OTHER MICROTOME ACCESSORIES MARKET, BY REGION,
2017–2020 (USD MILLION) 88
TABLE 37 OTHER MICROTOME ACCESSORIES MARKET, BY REGION,
2021–2027 (USD MILLION) 88
7 MICROTOMES MARKET, BY TECHNOLOGY 89
7.1 INTRODUCTION 90
TABLE 38 MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 90
TABLE 39 MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 90
7.2 MANUAL MICROTOMES 90
7.2.1 LOWER COST AND USER COMFORT ASSOCIATED WITH THESE MICROTOMES ARE DRIVING THEIR ADOPTION 90
TABLE 40 MANUAL MICROTOMES OFFERED BY MARKET PLAYERS 91
TABLE 41 MANUAL MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION) 91
TABLE 42 MANUAL MICROTOMES MARKET, BY REGION, 2021–2027 USD MILLION) 91
7.3 SEMI-AUTOMATED MICROTOMES 92
7.3.1 SEMI-AUTOMATED MICROTOMES SEGMENT TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 92
TABLE 43 SEMI-AUTOMATED MICROTOMES OFFERED BY MARKET PLAYERS 92
TABLE 44 SEMI-AUTOMATED MICROTOMES MARKET, BY REGION,
2017–2020 (USD MILLION) 92
TABLE 45 SEMI-AUTOMATED MICROTOMES MARKET, BY REGION,
2021–2027 (USD MILLION) 93
7.4 FULLY AUTOMATED MICROTOMES 93
7.4.1 LACK OF CLINICAL LABORATORY TECHNICIANS AND HIGH PREVALENCE OF CANCER HAVE DRIVEN SEGMENT GROWTH 93
TABLE 46 FULLY AUTOMATED MICROTOMES OFFERED BY MARKET PLAYERS 93
TABLE 47 FULLY AUTOMATED MICROTOMES MARKET, BY REGION,
2017–2020 (USD MILLION) 94
TABLE 48 FULLY AUTOMATED MICROTOMES MARKET, BY REGION,
2021–2027 (USD MILLION) 94
8 MICROTOMES MARKET, BY APPLICATION 95
8.1 INTRODUCTION 96
TABLE 49 MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 96
TABLE 50 MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 96
8.2 DISEASE DIAGNOSIS 96
8.2.1 EXPANDING POOL OF GERIATRIC PATIENTS AND INCREASING DIAGNOSIS OF CHRONIC DISEASES DRIVING SEGMENT GROWTH 96
TABLE 51 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS.
2030 VS. 2040 (MILLION) 97
TABLE 52 MICROTOMES MARKET FOR DISEASE DIAGNOSIS, BY REGION,
2017–2020 (USD MILLION) 97
TABLE 53 MICROTOMES MARKET FOR DISEASE DIAGNOSIS, BY REGION,
2021–2027 (USD MILLION) 97
8.3 MEDICAL RESEARCH 98
8.3.1 INCREASING RESEARCH ACTIVITIES TO DRIVE ADOPTION OF MICROTOMES 98
TABLE 54 MICROTOMES MARKET FOR MEDICAL RESEARCH, BY REGION,
2017–2020 (USD MILLION) 98
TABLE 55 MICROTOMES MARKET FOR MEDICAL RESEARCH, BY REGION,
2021–2027 (USD MILLION) 98
9 MICROTOMES MARKET, BY END USER 99
9.1 INTRODUCTION 100
TABLE 56 MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 100
TABLE 57 MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 100
9.2 HOSPITAL LABORATORIES 100
9.2.1 HOSPITAL LABORATORIES ACCOUNTED FOR LARGEST
MARKET SHARE IN 2021 100
TABLE 58 MICROTOMES MARKET FOR HOSPITAL LABORATORIES, BY REGION,
2017–2020 (USD MILLION) 101
TABLE 59 MICROTOMES MARKET FOR HOSPITAL LABORATORIES, BY REGION,
2021–2027 (USD MILLION) 101
9.3 CLINICAL LABORATORIES 102
9.3.1 PRESENCE OF ROBUST INFRASTRUCTURE TO PERFORM TESTS IN HIGH VOLUMES IS ESTIMATED TO DRIVE MARKET GROWTH 102
TABLE 60 MICROTOMES MARKET FOR CLINICAL LABORATORIES, BY REGION,
2017–2020 (USD MILLION) 102
TABLE 61 MICROTOMES MARKET FOR CLINICAL LABORATORIES, BY REGION,
2021–2027 (USD MILLION) 102
9.4 OTHER END USERS 103
TABLE 62 MICROTOMES MARKET FOR OTHER END USERS, BY REGION,
2017–2020 (USD MILLION) 103
TABLE 63 MICROTOMES MARKET FOR OTHER END USERS, BY REGION,
2021–2027 (USD MILLION) 103
10 MICROTOMES MARKET, BY REGION 104
10.1 INTRODUCTION 105
TABLE 64 MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION) 105
TABLE 65 MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION) 105
10.2 NORTH AMERICA 106
FIGURE 27 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035 106
FIGURE 28 NORTH AMERICA: MICROTOMES MARKET SNAPSHOT 107
TABLE 66 NORTH AMERICA: MICROTOMES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 108
TABLE 67 NORTH AMERICA: MICROTOMES MARKET, BY COUNTRY,
2021–2027 (USD MILLION) 108
TABLE 68 NORTH AMERICA: MICROTOMES MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 108
TABLE 69 NORTH AMERICA: MICROTOMES MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 108
TABLE 70 NORTH AMERICA: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2017–2020 (USD MILLION) 109
TABLE 71 NORTH AMERICA: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2021–2027 (USD MILLION) 109
TABLE 72 NORTH AMERICA: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 109
TABLE 73 NORTH AMERICA: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 110
TABLE 74 NORTH AMERICA: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 110
TABLE 75 NORTH AMERICA: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 110
TABLE 76 NORTH AMERICA: MICROTOMES MARKET, BY END USER,
2017–2020 (USD MILLION) 110
TABLE 77 NORTH AMERICA: MICROTOMES MARKET, BY END USER,
2021–2027 (USD MILLION) 111
10.2.1 US 111
10.2.1.1 High burden of cancer and numerous conferences on anatomic pathology to drive market growth 111
TABLE 78 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 111
TABLE 79 US: KEY MACROINDICATORS 112
TABLE 80 US: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 112
TABLE 81 US: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 112
TABLE 82 US: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 113
TABLE 83 US: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 113
TABLE 84 US: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 113
TABLE 85 US: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 113
TABLE 86 US: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 114
TABLE 87 US: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 114
10.2.2 CANADA 114
10.2.2.1 Availability of research funding and rising incidence of cancer to drive market growth 114
TABLE 88 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 115
TABLE 89 CANADA: KEY MACROINDICATORS 115
TABLE 90 CANADA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 115
TABLE 91 CANADA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 116
TABLE 92 CANADA: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 116
TABLE 93 CANADA: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 116
TABLE 94 CANADA: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 116
TABLE 95 CANADA: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 117
TABLE 96 CANADA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 117
TABLE 97 CANADA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 117
10.3 EUROPE 117
FIGURE 29 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 118
TABLE 98 EUROPE: MICROTOMES MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 118
TABLE 99 EUROPE: MICROTOMES MARKET, BY COUNTRY, 2021–2027 (USD MILLION) 118
TABLE 100 EUROPE: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 119
TABLE 101 EUROPE: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 119
TABLE 102 EUROPE: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2017–2020 (USD MILLION) 119
TABLE 103 EUROPE: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2021–2027 (USD MILLION) 119
TABLE 104 EUROPE: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 120
TABLE 105 EUROPE: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 120
TABLE 106 EUROPE: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 120
TABLE 107 EUROPE: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 120
TABLE 108 EUROPE: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 121
TABLE 109 EUROPE: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 121
10.3.1 GERMANY 121
10.3.1.1 Increasing prevalence of chronic diseases to drive market growth 121
TABLE 110 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 122
TABLE 111 GERMANY: MICROTOMES MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 122
TABLE 112 GERMANY: MICROTOMES MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 122
TABLE 113 GERMANY: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 123
TABLE 114 GERMANY: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 123
TABLE 115 GERMANY: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 123
TABLE 116 GERMANY: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 123
TABLE 117 GERMANY: MICROTOMES MARKET, BY END USER,
2017–2020 (USD MILLION) 124
TABLE 118 GERMANY: MICROTOMES MARKET, BY END USER,
2021–2027 (USD MILLION) 124
10.3.2 FRANCE 124
10.3.2.1 High prevalence of cancer to support market growth in France 124
TABLE 119 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 125
TABLE 120 FRANCE: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 125
TABLE 121 FRANCE: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 125
TABLE 122 FRANCE: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 125
TABLE 123 FRANCE: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 126
TABLE 124 FRANCE: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 126
TABLE 125 FRANCE: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 126
TABLE 126 FRANCE: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 126
TABLE 127 FRANCE: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 127
10.3.3 UK 127
10.3.3.1 Favorable government initiatives to drive market growth 127
TABLE 128 UK: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 127
TABLE 129 UK: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 128
TABLE 130 UK: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 128
TABLE 131 UK: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 128
TABLE 132 UK: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 128
TABLE 133 UK: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 129
TABLE 134 UK: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 129
TABLE 135 UK: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 129
10.3.4 ITALY 129
10.3.4.1 High prevalence of cancer and increasing per capita healthcare spending to support market growth in Italy 129
TABLE 136 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 130
TABLE 137 ITALY: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 130
TABLE 138 ITALY: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 131
TABLE 139 ITALY: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 131
TABLE 140 ITALY: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 131
TABLE 141 ITALY: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 131
TABLE 142 ITALY: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 132
TABLE 143 ITALY: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 132
TABLE 144 ITALY: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 132
10.3.5 SPAIN 132
10.3.5.1 High incidence of chronic diseases to drive market growth in Spain 132
TABLE 145 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 133
TABLE 146 SPAIN: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 133
TABLE 147 SPAIN: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 133
TABLE 148 SPAIN: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 134
TABLE 149 SPAIN: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 134
TABLE 150 SPAIN: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 134
TABLE 151 SPAIN: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 134
TABLE 152 SPAIN: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 135
TABLE 153 SPAIN: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 135
10.3.6 REST OF EUROPE 135
TABLE 154 LUNG CANCER INCIDENCE IN KEY ROE COUNTRIES, 2020 VS. 2040 136
TABLE 155 LIVER CANCER INCIDENCE IN KEY ROE COUNTRIES, 2020 VS. 2040 136
TABLE 156 ROE: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 137
TABLE 157 ROE: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 137
TABLE 158 ROE: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 137
TABLE 159 ROE: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 137
TABLE 160 ROE: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 138
TABLE 161 ROE: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 138
TABLE 162 ROE: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 138
TABLE 163 ROE: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 138
10.4 ASIA PACIFIC 139
FIGURE 30 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035 139
FIGURE 31 ASIA PACIFIC: MICROTOMES MARKET SNAPSHOT 140
TABLE 164 ASIA PACIFIC: MICROTOMES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 140
TABLE 165 ASIA PACIFIC: MICROTOMES MARKET, BY COUNTRY,
2021–2027 (USD MILLION) 141
TABLE 166 ASIA PACIFIC: MICROTOMES MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 141
TABLE 167 ASIA PACIFIC: MICROTOMES MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 141
TABLE 168 ASIA PACIFIC: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2017–2020 (USD MILLION) 141
TABLE 169 ASIA PACIFIC: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2021–2027 (USD MILLION) 142
TABLE 170 ASIA PACIFIC: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 142
TABLE 171 ASIA PACIFIC: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 142
TABLE 172 ASIA PACIFIC: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 142
TABLE 173 ASIA PACIFIC: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 143
TABLE 174 ASIA PACIFIC: MICROTOMES MARKET, BY END USER,
2017–2020 (USD MILLION) 143
TABLE 175 ASIA PACIFIC: MICROTOMES MARKET, BY END USER,
2021–2027 (USD MILLION) 143
10.4.1 JAPAN 143
10.4.1.1 Presence of well-developed healthcare system to support market growth in Japan 143
TABLE 176 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 144
TABLE 177 JAPAN: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 144
TABLE 178 JAPAN: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 145
TABLE 179 JAPAN: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 145
TABLE 180 JAPAN: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 145
TABLE 181 JAPAN: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 145
TABLE 182 JAPAN: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 146
TABLE 183 JAPAN: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 146
TABLE 184 JAPAN: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 146
10.4.2 CHINA 146
10.4.2.1 Rising healthcare expenditure to drive market growth in China 146
TABLE 185 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 147
TABLE 186 CHINA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 147
TABLE 187 CHINA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 147
TABLE 188 CHINA: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 148
TABLE 189 CHINA: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 148
TABLE 190 CHINA: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 148
TABLE 191 CHINA: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 148
TABLE 192 CHINA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 149
TABLE 193 CHINA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 149
10.4.3 INDIA 149
10.4.3.1 Growing healthcare sector to drive market growth in India 149
TABLE 194 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 149
TABLE 195 INDIA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 150
TABLE 196 INDIA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 150
TABLE 197 INDIA: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 150
TABLE 198 INDIA: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 151
TABLE 199 INDIA: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 151
TABLE 200 INDIA: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 151
TABLE 201 INDIA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 151
TABLE 202 INDIA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 152
10.4.4 REST OF ASIA PACIFIC 152
TABLE 203 ROAPAC: INCIDENCE OF CANCER, BY COUNTRY, 2020 VS. 2040 153
TABLE 204 ROAPAC: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 153
TABLE 205 ROAPAC: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 153
TABLE 206 ROAPAC: MICROTOMES MARKET, BY APPLICATION,
2017–2020 (USD MILLION) 153
TABLE 207 ROAPAC: MICROTOMES MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 154
TABLE 208 ROAPAC: MICROTOMES MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 154
TABLE 209 ROAPAC: MICROTOMES MARKET, BY TECHNOLOGY,
2021–2027 (USD MILLION) 154
TABLE 210 ROAPAC: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 154
TABLE 211 ROAPAC: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 155
10.5 REST OF THE WORLD 155
TABLE 212 LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025 155
TABLE 213 LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025 155
TABLE 214 BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,
2018 VS. 2025 156
TABLE 215 AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 156
TABLE 216 ROW: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 156
TABLE 217 ROW: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 157
TABLE 218 ROW: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2017–2020 (USD MILLION) 157
TABLE 219 ROW: MICROTOME INSTRUMENTS MARKET, BY TYPE,
2021–2027 (USD MILLION) 157
TABLE 220 ROW: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 157
TABLE 221 ROW: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 158
TABLE 222 ROW: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 158
TABLE 223 ROW: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION) 158
TABLE 224 ROW: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION) 158
TABLE 225 ROW: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION) 159
11 COMPETITIVE LANDSCAPE 160
11.1 OVERVIEW 160
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 160
TABLE 226 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 160
11.3 MARKET SHARE ANALYSIS 161
TABLE 227 MICROTOMES MARKET: DEGREE OF COMPETITION 161
11.4 COMPANY EVALUATION MATRIX 162
11.4.1 STARS 162
11.4.2 EMERGING LEADERS 163
11.4.3 PERVASIVE PLAYERS 163
11.4.4 PARTICIPANTS 163
FIGURE 32 COMPANY EVALUATION MATRIX: MICROTOMES MARKET 163
11.5 COMPANY EVALUATION MATRIX FOR SMES/START-UPS 164
11.5.1 PROGRESSIVE COMPANIES 164
11.5.2 STARTING BLOCKS 164
11.5.3 RESPONSIVE COMPANIES 164
11.5.4 DYNAMIC COMPANIES 164
FIGURE 33 COMPANY EVALUATION MATRIX FOR SMES/START-UPS:
MICROTOMES MARKET 165
11.6 COMPANY FOOTPRINT ANALYSIS 166
TABLE 228 OVERALL FOOTPRINT OF COMPANIES 166
TABLE 229 REGIONAL FOOTPRINT OF COMPANIES 167
TABLE 230 PRODUCT FOOTPRINT OF COMPANIES 168
11.7 COMPETITIVE BENCHMARKING 169
TABLE 231 MICROTOMES MARKET: DETAILED LIST OF KEY START-UPS/SMES 169
11.8 COMPETITIVE SCENARIO 170
11.8.1 PRODUCT LAUNCHES 170
TABLE 232 KEY PRODUCT LAUNCHES 170
11.8.2 DEALS 170
TABLE 233 KEY DEALS 170
11.8.3 OTHER DEVELOPMENTS 170
TABLE 234 OTHER KEY DEVELOPMENTS 170
12 COMPANY PROFILES 171
12.1 KEY PLAYERS 171
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION 171
TABLE 235 DANAHER CORPORATION: BUSINESS OVERVIEW 171
FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 172
12.1.2 PHC HOLDINGS CORPORATION 175
TABLE 236 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW 175
FIGURE 35 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021) 176
12.1.3 CARDINAL HEALTH 178
TABLE 237 CARDINAL HEALTH: BUSINESS OVERVIEW 178
FIGURE 36 CARDINAL HEALTH: COMPANY SNAPSHOT (2021) 179
12.1.4 BOECKELER INSTRUMENTS, INC. 181
TABLE 238 BOECKELER INSTRUMENTS, INC.: BUSINESS OVERVIEW 181
12.1.5 BRIGHT INSTRUMENTS LTD. 183
TABLE 239 BRIGHT INSTRUMENTS LTD.: BUSINESS OVERVIEW 183
12.1.6 ERMA INC. 184
TABLE 240 ERMA INC.: BUSINESS OVERVIEW 184
12.1.7 HISTO-LINE LABORATORIES 185
TABLE 241 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW 185
12.1.8 JINHUA YIDI MEDICAL APPLIANCE CO., LTD. 187
TABLE 242 JINHUA YIDI MEDICAL APPLIANCE CO., LTD.: BUSINESS OVERVIEW 187
12.1.9 MEDIMEAS 189
TABLE 243 MEDIMEAS: BUSINESS OVERVIEW 189
12.1.10 MEDITE MEDICAL GMBH 191
TABLE 244 MEDITE MEDICAL GMBH: BUSINESS OVERVIEW 191
12.1.11 MICROTEC LABORGERÄTE GMBH 192
TABLE 245 MICROTEC LABORGERÄTE GMBH: BUSINESS OVERVIEW 192
12.1.12 SAKURA FINETEK USA, INC. 194
TABLE 246 SAKURA FINETEK USA, INC.: BUSINESS OVERVIEW 194
12.1.13 SLEE MEDICAL GMBH 196
TABLE 247 SLEE MEDICAL GMBH: BUSINESS OVERVIEW 196
12.1.14 SM SCIENTIFIC INSTRUMENTS PVT. LTD. 198
TABLE 248 SM SCIENTIFIC INSTRUMENTS PVT. LTD.: BUSINESS OVERVIEW 198
12.1.15 TED PELLA, INC. 200
TABLE 249 TED PELLA, INC.: BUSINESS OVERVIEW 200
12.2 OTHER PLAYERS 202
12.2.1 AGD BIOMEDICALS PVT. LTD. 202
TABLE 250 AGD BIOMEDICALS PVT. LTD.: BUSINESS OVERVIEW 202
12.2.2 AMOS SCIENTIFIC PTY LTD. 203
TABLE 251 AMOS SCIENTIFIC PTY LTD.: BUSINESS OVERVIEW 203
12.2.3 CAMPDEN INSTRUMENTS LTD. 204
TABLE 252 CAMPDEN INSTRUMENTS LTD.: BUSINESS OVERVIEW 204
12.2.4 DIAPATH S.P.A. 205
TABLE 253 DIAPATH S.P.A.: BUSINESS OVERVIEW 205
12.2.5 LABOID INTERNATIONAL 207
TABLE 254 LABOID INTERNATIONAL: BUSINESS OVERVIEW 207
12.2.6 LAFAYETTE INSTRUMENT COMPANY 208
TABLE 255 LAFAYETTE INSTRUMENT COMPANY: BUSINESS OVERVIEW 208
12.2.7 LUPETEC 209
TABLE 256 LUPETEC: BUSINESS OVERVIEW 209
12.2.8 MILESTONE MEDICAL 210
TABLE 257 MILESTONE MEDICAL: BUSINESS OVERVIEW 210
12.2.9 RWD LIFE SCIENCE CO., LTD. 211
TABLE 258 RWD LIFE SCIENCE CO., LTD.: BUSINESS OVERVIEW 211
12.2.10 SHENZHEN DAKEWEI BIOTECHNOLOGY CO., LTD. 212
TABLE 259 SHENZHEN DAKEWEI BIOTECHNOLOGY CO., LTD.: BUSINESS OVERVIEW 212
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 213
13.1 DISCUSSION GUIDE 213
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 216
13.3 AVAILABLE CUSTOMIZATIONS 218
13.4 RELATED REPORTS 218
13.5 AUTHOR DETAILS 219

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（消費財）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（instruments）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22　10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.